H.C. Wainwright Reiterates Their Hold Rating on Sunesis Pharma (SNSS)


H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Sunesis Pharma (SNSS) today and set a price target of $0.50. The company’s shares closed yesterday at $0.63, close to its 52-week low of $0.20.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.5% and a 48.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Sunesis Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $3.25.

See today’s analyst top recommended stocks >>

Based on Sunesis Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $6 million. In comparison, last year the company had a GAAP net loss of $6.62 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts